AstraZeneca expanded its China play with two coordinated moves: a broad investment commitment and a targeted licensing pact. The company agreed a strategic collaboration with CSPC that pays $1.2 billion upfront for rights to an eight‑asset portfolio of long‑acting, once‑monthly GLP‑1/GIP peptide candidates and platform tech, including a Phase 1–ready asset. Separately, AZ outlined a $15 billion long‑term investment to scale R&D and manufacturing in China through 2030. The CSPC deal gives AstraZeneca immediate program breadth in weight‑management modalities and long‑acting delivery technology while leaving China commercialization rights partly with CSPC—a structure that accelerates global development without displacing local partners. AZ’s $15 billion commitment targets capacity and local innovation, signaling a dual strategy of inorganic asset access plus in‑market scaling. Both moves underscore multinational pharmas’ increasing reliance on Chinese biotech partnerships and regional manufacturing to secure late‑stage supply and accelerate global launches.